摘要
多发性骨髓瘤(MM)是一种血液恶性肿瘤,其特征为恶性浆细胞的克隆性增殖。蛋白酶体抑制剂、免疫调节药物以及自体造血干细胞移植治疗明显改善了MM患者的生活质量和生存状况,然而几乎所有患者都将产生耐药导致疾病复发难治,预后较差。因此,探究MM患者耐药性产生的分子机制,寻找新的治疗靶点并开发新的靶向治疗策略尤为重要。现对MM耐药机制和分子靶向治疗研究的最新进展进行综述。
Objective Multiple myeloma(MM)is a hematologic malignancy characterized by clonal proliferation of malignant plasma cells.Proteasome inhibitors,immunomodulatory drugs and autologous hematopoietic stem cell transplantation have significantly improved the quality of life and survival of MM patients.However,almost all patients will develop drug resistance,leading to difficult disease recurrence and poor prognosis.Therefore,it is particularly important to explore the molecular mechanism of drug resistance in MM patients,search for new therapeutic targets and develop new targeted therapeutic strategies.This article reviews the recent progress in the research of MM resistance mechanism and molecular targeted therapy.
作者
马静远
郝牧
MA Jingyuan;HAO Mu(State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China;Tianjin Institutes of Health Science,Tianjin 301600,China)
出处
《转化医学杂志》
2024年第2期292-295,共4页
Translational Medicine Journal
基金
国家自然科学基金资助项目(82370210,82170194)。
关键词
多发性骨髓瘤
抗药性
肿瘤
分子靶向治疗
综述
蛋白酶体抑制剂
免疫调节药物
维奈克拉
嵌合抗原受体
Multiple myeloma
Drug resistance,neoplasm
Molecular targeted therapy
Review
Proteasome inhibitors
Immunomodulatory drugs
Venetoclax
Chimeric antigen receptor
